Selected research
Market Structure
Global Recombinant Plasma Protein Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Recombinant Plasma Protein Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Recombinant Plasma Protein Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Recombinant Plasma Protein Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Recombinant Plasma Protein Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Recombinant Plasma Protein Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Recombinant Plasma Protein Therapeutics include Takeda, Novo Nordisk A/S, Pfizer, Pharming Group, Octapharma, CSL Limited, Bioverativ Therapeutics and Aptevo Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Recombinant Plasma Protein Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Recombinant Plasma Protein Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Recombinant Plasma Protein Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Plasma Protein Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.
Recombinant Plasma Protein Therapeutics Segment by Company
Takeda
Novo Nordisk A/S
Pfizer
Pharming Group
Octapharma
CSL Limited
Bioverativ Therapeutics
Aptevo Therapeutics
Recombinant Plasma Protein Therapeutics Segment by Type
Recombinant Coagulation Factors
Human C1 Esterase Inhibitor
Recombinant Plasma Protein Therapeutics Segment by Application
Von Willebrand Disease
Hemophilia A
Hemophilia B
Recombinant Plasma Protein Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Plasma Protein Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Plasma Protein Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Plasma Protein Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Recombinant Plasma Protein Therapeutics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Plasma Protein Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Plasma Protein Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Recombinant Plasma Protein Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Recombinant Coagulation Factors
- Human C1 Esterase Inhibitor
Applications
- Von Willebrand Disease
- Hemophilia A
- Hemophilia B
Companies covered
- Takeda
- Novo Nordisk A/S
- Pfizer
- Pharming Group
- Octapharma
- CSL Limited
- Bioverativ Therapeutics
- Aptevo Therapeutics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Recombinant Plasma Protein Therapeutics Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Recombinant Plasma Protein Therapeutics Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Recombinant Plasma Protein Therapeutics Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Recombinant Plasma Protein Therapeutics Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Recombinant Plasma Protein Therapeutics Market Dynamics
- 2.1 Recombinant Plasma Protein Therapeutics Industry Trends
- 2.2 Recombinant Plasma Protein Therapeutics Industry Drivers
- 2.3 Recombinant Plasma Protein Therapeutics Industry Opportunities and Challenges
- 2.4 Recombinant Plasma Protein Therapeutics Industry Restraints
3 Recombinant Plasma Protein Therapeutics Market by Manufacturers
- 3.1 Global Recombinant Plasma Protein Therapeutics Revenue by Manufacturers (2021-2026)
- 3.2 Global Recombinant Plasma Protein Therapeutics Sales by Manufacturers (2021-2026)
- 3.3 Global Recombinant Plasma Protein Therapeutics Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Recombinant Plasma Protein Therapeutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Recombinant Plasma Protein Therapeutics Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Recombinant Plasma Protein Therapeutics Manufacturers, Product Type & Application
- 3.7 Global Recombinant Plasma Protein Therapeutics Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Recombinant Plasma Protein Therapeutics Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Recombinant Plasma Protein Therapeutics Players Market Share by Revenue in 2025
- 3.8.3 2025 Recombinant Plasma Protein Therapeutics Tier 1, Tier 2, and Tier 3
4 Recombinant Plasma Protein Therapeutics Market by Type
- 4.1 Recombinant Plasma Protein Therapeutics Type Introduction
- 4.1.1 Recombinant Coagulation Factors
- 4.1.2 Human C1 Esterase Inhibitor
- 4.2 Global Recombinant Plasma Protein Therapeutics Sales by Type
- 4.2.1 Global Recombinant Plasma Protein Therapeutics Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Recombinant Plasma Protein Therapeutics Sales by Type (2021-2032)
- 4.2.3 Global Recombinant Plasma Protein Therapeutics Sales Market Share by Type (2021-2032)
- 4.3 Global Recombinant Plasma Protein Therapeutics Revenue by Type
- 4.3.1 Global Recombinant Plasma Protein Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Recombinant Plasma Protein Therapeutics Revenue by Type (2021-2032)
- 4.3.3 Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Type (2021-2032)
5 Recombinant Plasma Protein Therapeutics Market by Application
- 5.1 Recombinant Plasma Protein Therapeutics Application Introduction
- 5.1.1 Von Willebrand Disease
- 5.1.2 Hemophilia A
- 5.1.3 Hemophilia B
- 5.2 Global Recombinant Plasma Protein Therapeutics Sales by Application
- 5.2.1 Global Recombinant Plasma Protein Therapeutics Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Recombinant Plasma Protein Therapeutics Sales by Application (2021-2032)
- 5.2.3 Global Recombinant Plasma Protein Therapeutics Sales Market Share by Application (2021-2032)
- 5.3 Global Recombinant Plasma Protein Therapeutics Revenue by Application
- 5.3.1 Global Recombinant Plasma Protein Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Recombinant Plasma Protein Therapeutics Revenue by Application (2021-2032)
- 5.3.3 Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Application (2021-2032)
6 Global Recombinant Plasma Protein Therapeutics Sales by Region
- 6.1 Global Recombinant Plasma Protein Therapeutics Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Recombinant Plasma Protein Therapeutics Sales by Region (2021-2032)
- 6.2.1 Global Recombinant Plasma Protein Therapeutics Sales by Region (2021-2026)
- 6.2.2 Global Recombinant Plasma Protein Therapeutics Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Recombinant Plasma Protein Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Recombinant Plasma Protein Therapeutics Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Recombinant Plasma Protein Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Recombinant Plasma Protein Therapeutics Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Recombinant Plasma Protein Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Recombinant Plasma Protein Therapeutics Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Recombinant Plasma Protein Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Recombinant Plasma Protein Therapeutics Revenue by Region
- 7.1 Global Recombinant Plasma Protein Therapeutics Revenue by Region
- 7.1.1 Global Recombinant Plasma Protein Therapeutics Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Recombinant Plasma Protein Therapeutics Revenue by Region (2021-2026)
- 7.1.3 Global Recombinant Plasma Protein Therapeutics Revenue by Region (2027-2032)
- 7.1.4 Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Recombinant Plasma Protein Therapeutics Revenue (2021-2032)
- 7.2.2 North America Recombinant Plasma Protein Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Recombinant Plasma Protein Therapeutics Revenue (2021-2032)
- 7.3.2 Europe Recombinant Plasma Protein Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Recombinant Plasma Protein Therapeutics Revenue (2021-2032)
- 7.4.2 Asia-Pacific Recombinant Plasma Protein Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Takeda
- 8.1.1 Takeda Company Information
- 8.1.2 Takeda Business Overview
- 8.1.3 Takeda Recombinant Plasma Protein Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Takeda Recombinant Plasma Protein Therapeutics Product Portfolio
- 8.1.5 Takeda Recent Developments
- 8.2 Novo Nordisk A/S
- 8.2.1 Novo Nordisk A/S Company Information
- 8.2.2 Novo Nordisk A/S Business Overview
- 8.2.3 Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Product Portfolio
- 8.2.5 Novo Nordisk A/S Recent Developments
- 8.3 Pfizer
- 8.3.1 Pfizer Company Information
- 8.3.2 Pfizer Business Overview
- 8.3.3 Pfizer Recombinant Plasma Protein Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Pfizer Recombinant Plasma Protein Therapeutics Product Portfolio
- 8.3.5 Pfizer Recent Developments
- 8.4 Pharming Group
- 8.4.1 Pharming Group Company Information
- 8.4.2 Pharming Group Business Overview
- 8.4.3 Pharming Group Recombinant Plasma Protein Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Pharming Group Recombinant Plasma Protein Therapeutics Product Portfolio
- 8.4.5 Pharming Group Recent Developments
- 8.5 Octapharma
- 8.5.1 Octapharma Company Information
- 8.5.2 Octapharma Business Overview
- 8.5.3 Octapharma Recombinant Plasma Protein Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Octapharma Recombinant Plasma Protein Therapeutics Product Portfolio
- 8.5.5 Octapharma Recent Developments
- 8.6 CSL Limited
- 8.6.1 CSL Limited Company Information
- 8.6.2 CSL Limited Business Overview
- 8.6.3 CSL Limited Recombinant Plasma Protein Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 CSL Limited Recombinant Plasma Protein Therapeutics Product Portfolio
- 8.6.5 CSL Limited Recent Developments
- 8.7 Bioverativ Therapeutics
- 8.7.1 Bioverativ Therapeutics Company Information
- 8.7.2 Bioverativ Therapeutics Business Overview
- 8.7.3 Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Product Portfolio
- 8.7.5 Bioverativ Therapeutics Recent Developments
- 8.8 Aptevo Therapeutics
- 8.8.1 Aptevo Therapeutics Company Information
- 8.8.2 Aptevo Therapeutics Business Overview
- 8.8.3 Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Product Portfolio
- 8.8.5 Aptevo Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Recombinant Plasma Protein Therapeutics Value Chain Analysis
- 9.1.1 Recombinant Plasma Protein Therapeutics Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Recombinant Plasma Protein Therapeutics Production Mode & Process
- 9.2 Recombinant Plasma Protein Therapeutics Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Recombinant Plasma Protein Therapeutics Distributors
- 9.2.3 Recombinant Plasma Protein Therapeutics Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst